Biopharmaceuticals are intensely focused on efficiency and time to market; however, the nature of clinical trials continues to present obstacles to attaining these goals. Today’s trials are still far too costly, and study cycle times remain too long to achieve a recoverable time to market. In response, many biopharmaceuticals are focused on reducing study cycle time by pinpointing the right countries, sites and patients. Paul Evans and Xavier Flinois at Parexel share their thoughts with the public on technology advances in feasibility, recruitment and retention.